Evanoa Bioscience

Evanoa Bioscience is a private, pre-revenue platform company founded in 2019 and headquartered in Alachua, Florida. The company's core asset is a novel, proprietary technology for engineering cell lines (including E. coli, S. cerevisiae, SF9, CHO, and HEK293) to achieve order-of-magnitude improvements in productivity for biologics manufacturing. Its business model revolves around licensing these improved cell lines to partners such as CDMOs, pharmaceutical, and biotechnology companies, as evidenced by its 2023 licensing agreement with Aldevron for specialized E. coli strains used in plasmid DNA production. Evanoa aims to become a key enabler in the biomanufacturing supply chain by providing foundational tools that increase the efficiency and scalability of therapeutic production.

Proprietary cell line engineering platform for order-of-magnitude improvements in yield, growth rate, and process tolerance for biopharmaceutical production in microbial and mammalian systems.

Evanoa competes in the cell line development market against large life science tools companies (e.g., Sartorius, Thermo Fisher), specialized CDMOs with proprietary platforms, and academic spin-outs. Its differentiation claims are based on the magnitude of improvement and broad applicability of its proprietary engineering technology across diverse host systems.